<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959361</url>
  </required_header>
  <id_info>
    <org_study_id>2003164</org_study_id>
    <nct_id>NCT00959361</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness of Pharmaceutical Care on the Adherence of HIV-Positive Patients to Antiretroviral Therapy</brief_title>
  <acronym>PC-HIV</acronym>
  <official_title>Evaluation of Effectiveness of Pharmaceutical Care on the Adherence of HIV-Positive Patients to Antiretroviral Therapy - Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal University of Rio Grande do Sul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INTRODUCTION: Studies prove that the pharmaceutical care (PC) increases the adherence to the&#xD;
      antiretroviral; thus, they increase the undetectable viral load. The viral load diminishes,&#xD;
      and the prevalence of undetectable viral load increases, as the levels of adherence to the&#xD;
      treatment increase, being in general necessary high adhesion to reach the effectiveness&#xD;
      therapeutic. Increasing the adherence levels, it increases the surviving chances and quality&#xD;
      of life and diminishes the transmission risks. Studies demonstrate that the&#xD;
      self-effectiveness expectation to use the medication correctly is the main predictor of&#xD;
      adherence, and that the more complex the therapeutic regimen is, and the perception of side&#xD;
      effects, the smaller the adherence is, highlighting the importance of preventing, identifying&#xD;
      and solving the problems during the treatment with antiretroviral, problems related to the&#xD;
      medication (PRM) through the PC.&#xD;
&#xD;
      OBJECTIVES: To evaluate the effectiveness of the PC on the adherence of HIV-patients to the&#xD;
      antiretroviral therapy, identify, prevent and solve PRMs during the treatment.&#xD;
&#xD;
      METHODOLOGY: One-side randomized clinical trail controlled by non-intervention in parallel.&#xD;
      332 patients randomized are included in the control and intervention groups (PC).&#xD;
      Questionnaires will be applied: sociodemographic, adherence to the antiretroviral through&#xD;
      self-report, smoke, BECK (depression), CAGE (problems related with alcohol consumption) of&#xD;
      self-effectiveness, expectation of results and social support. Each 4 months measure of viral&#xD;
      load and CD4 will be carried out. The ones from the PC group will receive a card with&#xD;
      information about the medication and all the medicines will be identified by different&#xD;
      colors. The follow-up will last one year according to the instructions of DADER program.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Election of the sample: 332 will be selected consecutively patients registered in the&#xD;
      SAE-Pelotas&#xD;
&#xD;
      GENERAL OBJECTIVE To evaluate the effectiveness of Pharmaceutical Care on the adherence to&#xD;
      the antiretroviral therapy in HIV- positive patients.&#xD;
&#xD;
      PRIMARY OBJECTIVE The relative risk for adherence to the antiretroviral treatment among&#xD;
      HIV-positive patients who receive Pharmaceutical Care and the ones that do not receive&#xD;
      Pharmaceutical Care is different of 1.&#xD;
&#xD;
      SECONDARY OBJECTIVE The relative risk for undetectable viral load among HIV-positive patients&#xD;
      that receive Pharmaceutical Care and the ones that do not receive Pharmaceutical Care is&#xD;
      different of 1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative risk for adherence to the antiretroviral treatment among HIV-positive patients who receive Pharmaceutical Care and the ones that do not receive Pharmaceutical</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">332</enrollment>
  <condition>HIV</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>pharmaceutical care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>consultation with the pharmacists</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>usual care without consultation with the pharmacists</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>pharmaceutical care</intervention_name>
    <description>consultation with the pharmacists and usual care</description>
    <arm_group_label>pharmaceutical care</arm_group_label>
    <other_name>pharmaceutical attention</other_name>
    <other_name>DADER method</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients registered in the SAE-Pelotas&#xD;
&#xD;
          -  adults (older 18 years)&#xD;
&#xD;
          -  inhabitants of the urban zone of Pelotas&#xD;
&#xD;
          -  not pregnant&#xD;
&#xD;
          -  in use of antiretroviral treatment&#xD;
&#xD;
          -  independent of the time of treatment&#xD;
&#xD;
          -  accept to participate in the research through the signature of a written informed&#xD;
             consent&#xD;
&#xD;
        The enclosed patients will be randomized through program computerized for the group of&#xD;
        pharmaceutical care or control group.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  non signature of a written informed consent&#xD;
&#xD;
          -  incapacity to answer to the instruments of data collection&#xD;
&#xD;
          -  inhabitants are of the urban zone of Pelotas&#xD;
&#xD;
          -  patients who could not be followed by 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LEILA B MOREIRA, DR</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOSPITAL DE CLÍNICAS DE PORTO ALEGRE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <study_first_submitted>August 13, 2009</study_first_submitted>
  <study_first_submitted_qc>August 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2009</study_first_posted>
  <last_update_submitted>September 28, 2009</last_update_submitted>
  <last_update_submitted_qc>September 28, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Marysabel Pinto Telis Silveira</name_title>
    <organization>Universidade Católica de Pelotas</organization>
  </responsible_party>
  <keyword>patient compliance</keyword>
  <keyword>guidelines adherence</keyword>
  <keyword>advance directive adherence</keyword>
  <keyword>treatment refusal</keyword>
  <keyword>directly observed therapy</keyword>
  <keyword>anti-retroviral agents</keyword>
  <keyword>HIV seropositivity</keyword>
  <keyword>HIV infections</keyword>
  <keyword>HIV</keyword>
  <keyword>pharmaceutical services</keyword>
  <keyword>HIV-positives patients</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

